Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug

Rogerio R. Sotelo-Mundo, Joanna Ciesla, Jolanta M. Dzik, Wojciech Rode, Frank Maley, Gladys F. Maley, Larry W. Hardy, William "Bill" Montfort

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Two crystal structures of rat thymidylate synthase (TS) complexed with dUMP and the anticancer drug Tomudex (ZD1694) have been determined to resolutions of 3.3 and 2.6 Å. Tomudex is one of several new antifolates targeted to TS and the first to be approved for clinical use. The structures represent the first views of any mammalian TS bound to ligands and suggest that the rat protein undergoes a ligand-induced conformational change similar to that of the Escherichia coli protein. Surprisingly, Tomudex does not induce the 'closed' conformation in rat TS that is seen on binding to E. coli TS, resulting in inhibitor atoms that differ in position by more than 1.5 Å. Several species-specific differences in sequence may be the reason for this. Phe 74 shifts to a new position in the rat complex and is in van der Waals contact with the inhibitor, while in the E. coli protein the equivalent amino acid (His 51) hydrogen bonds to the glutamate portion of the inhibitor. Amino acids Arg 101, Asn 106, and Met 305 make no contacts with the inhibitor in the open conformation, unlike the equivalent residues in the E. coli protein (Thr 78, Trp 83, and Val 262). dUMP binding is similar in both proteins, except that there is no covalent adduct to the active site cysteine (Cys 189) in the rat structures. Two insertions in the rat protein are clearly seen, but the N-termini (residues 1-20) and C-termini (residues 301-307) are disordered in both crystal forms.

Original languageEnglish (US)
Pages (from-to)1087-1094
Number of pages8
JournalBiochemistry
Volume38
Issue number3
DOIs
StatePublished - Jan 19 1999

Fingerprint

Thymidylate Synthase
Rats
Crystal structure
Escherichia coli Proteins
Pharmaceutical Preparations
Conformations
Ligands
Folic Acid Antagonists
Amino Acids
Escherichia coli
Cysteine
Glutamic Acid
Hydrogen
Catalytic Domain
Hydrogen bonds
Proteins
raltitrexed
Atoms
Crystals

ASJC Scopus subject areas

  • Biochemistry

Cite this

Sotelo-Mundo, R. R., Ciesla, J., Dzik, J. M., Rode, W., Maley, F., Maley, G. F., ... Montfort, W. B. (1999). Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug. Biochemistry, 38(3), 1087-1094. https://doi.org/10.1021/bi981881d

Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug. / Sotelo-Mundo, Rogerio R.; Ciesla, Joanna; Dzik, Jolanta M.; Rode, Wojciech; Maley, Frank; Maley, Gladys F.; Hardy, Larry W.; Montfort, William "Bill".

In: Biochemistry, Vol. 38, No. 3, 19.01.1999, p. 1087-1094.

Research output: Contribution to journalArticle

Sotelo-Mundo, RR, Ciesla, J, Dzik, JM, Rode, W, Maley, F, Maley, GF, Hardy, LW & Montfort, WB 1999, 'Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug', Biochemistry, vol. 38, no. 3, pp. 1087-1094. https://doi.org/10.1021/bi981881d
Sotelo-Mundo RR, Ciesla J, Dzik JM, Rode W, Maley F, Maley GF et al. Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug. Biochemistry. 1999 Jan 19;38(3):1087-1094. https://doi.org/10.1021/bi981881d
Sotelo-Mundo, Rogerio R. ; Ciesla, Joanna ; Dzik, Jolanta M. ; Rode, Wojciech ; Maley, Frank ; Maley, Gladys F. ; Hardy, Larry W. ; Montfort, William "Bill". / Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug. In: Biochemistry. 1999 ; Vol. 38, No. 3. pp. 1087-1094.
@article{4e756fc4fcc94018b05c3ba41b029876,
title = "Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug",
abstract = "Two crystal structures of rat thymidylate synthase (TS) complexed with dUMP and the anticancer drug Tomudex (ZD1694) have been determined to resolutions of 3.3 and 2.6 {\AA}. Tomudex is one of several new antifolates targeted to TS and the first to be approved for clinical use. The structures represent the first views of any mammalian TS bound to ligands and suggest that the rat protein undergoes a ligand-induced conformational change similar to that of the Escherichia coli protein. Surprisingly, Tomudex does not induce the 'closed' conformation in rat TS that is seen on binding to E. coli TS, resulting in inhibitor atoms that differ in position by more than 1.5 {\AA}. Several species-specific differences in sequence may be the reason for this. Phe 74 shifts to a new position in the rat complex and is in van der Waals contact with the inhibitor, while in the E. coli protein the equivalent amino acid (His 51) hydrogen bonds to the glutamate portion of the inhibitor. Amino acids Arg 101, Asn 106, and Met 305 make no contacts with the inhibitor in the open conformation, unlike the equivalent residues in the E. coli protein (Thr 78, Trp 83, and Val 262). dUMP binding is similar in both proteins, except that there is no covalent adduct to the active site cysteine (Cys 189) in the rat structures. Two insertions in the rat protein are clearly seen, but the N-termini (residues 1-20) and C-termini (residues 301-307) are disordered in both crystal forms.",
author = "Sotelo-Mundo, {Rogerio R.} and Joanna Ciesla and Dzik, {Jolanta M.} and Wojciech Rode and Frank Maley and Maley, {Gladys F.} and Hardy, {Larry W.} and Montfort, {William {"}Bill{"}}",
year = "1999",
month = "1",
day = "19",
doi = "10.1021/bi981881d",
language = "English (US)",
volume = "38",
pages = "1087--1094",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug

AU - Sotelo-Mundo, Rogerio R.

AU - Ciesla, Joanna

AU - Dzik, Jolanta M.

AU - Rode, Wojciech

AU - Maley, Frank

AU - Maley, Gladys F.

AU - Hardy, Larry W.

AU - Montfort, William "Bill"

PY - 1999/1/19

Y1 - 1999/1/19

N2 - Two crystal structures of rat thymidylate synthase (TS) complexed with dUMP and the anticancer drug Tomudex (ZD1694) have been determined to resolutions of 3.3 and 2.6 Å. Tomudex is one of several new antifolates targeted to TS and the first to be approved for clinical use. The structures represent the first views of any mammalian TS bound to ligands and suggest that the rat protein undergoes a ligand-induced conformational change similar to that of the Escherichia coli protein. Surprisingly, Tomudex does not induce the 'closed' conformation in rat TS that is seen on binding to E. coli TS, resulting in inhibitor atoms that differ in position by more than 1.5 Å. Several species-specific differences in sequence may be the reason for this. Phe 74 shifts to a new position in the rat complex and is in van der Waals contact with the inhibitor, while in the E. coli protein the equivalent amino acid (His 51) hydrogen bonds to the glutamate portion of the inhibitor. Amino acids Arg 101, Asn 106, and Met 305 make no contacts with the inhibitor in the open conformation, unlike the equivalent residues in the E. coli protein (Thr 78, Trp 83, and Val 262). dUMP binding is similar in both proteins, except that there is no covalent adduct to the active site cysteine (Cys 189) in the rat structures. Two insertions in the rat protein are clearly seen, but the N-termini (residues 1-20) and C-termini (residues 301-307) are disordered in both crystal forms.

AB - Two crystal structures of rat thymidylate synthase (TS) complexed with dUMP and the anticancer drug Tomudex (ZD1694) have been determined to resolutions of 3.3 and 2.6 Å. Tomudex is one of several new antifolates targeted to TS and the first to be approved for clinical use. The structures represent the first views of any mammalian TS bound to ligands and suggest that the rat protein undergoes a ligand-induced conformational change similar to that of the Escherichia coli protein. Surprisingly, Tomudex does not induce the 'closed' conformation in rat TS that is seen on binding to E. coli TS, resulting in inhibitor atoms that differ in position by more than 1.5 Å. Several species-specific differences in sequence may be the reason for this. Phe 74 shifts to a new position in the rat complex and is in van der Waals contact with the inhibitor, while in the E. coli protein the equivalent amino acid (His 51) hydrogen bonds to the glutamate portion of the inhibitor. Amino acids Arg 101, Asn 106, and Met 305 make no contacts with the inhibitor in the open conformation, unlike the equivalent residues in the E. coli protein (Thr 78, Trp 83, and Val 262). dUMP binding is similar in both proteins, except that there is no covalent adduct to the active site cysteine (Cys 189) in the rat structures. Two insertions in the rat protein are clearly seen, but the N-termini (residues 1-20) and C-termini (residues 301-307) are disordered in both crystal forms.

UR - http://www.scopus.com/inward/record.url?scp=0033579809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033579809&partnerID=8YFLogxK

U2 - 10.1021/bi981881d

DO - 10.1021/bi981881d

M3 - Article

C2 - 9894005

AN - SCOPUS:0033579809

VL - 38

SP - 1087

EP - 1094

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 3

ER -